Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evotec Ag Ads (EVTCY)

Evotec Ag Ads (EVTCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,729,425
  • Shares Outstanding, K 75,574
  • Annual Sales, $ 443,350 K
  • Annual Income, $ 99,410 K
  • 60-Month Beta 1.20
  • Price/Sales 7.73
  • Price/Cash Flow 25.82
  • Price/Book 6.85
  • Price/Earnings ttm 57.70
  • Earnings Per Share ttm 0.82
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/17/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +208,025.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.3100 +1.88%
on 02/25/20
57.7800 -16.58%
on 02/11/20
-5.8000 (-10.74%)
since 01/24/20
3-Month
42.7000 +12.88%
on 12/02/19
57.7800 -16.58%
on 02/11/20
+5.4000 (+12.62%)
since 11/26/19
52-Week
40.6700 +18.51%
on 11/15/19
59.5000 -18.99%
on 07/29/19
+1.8000 (+3.88%)
since 02/27/19

Most Recent Stories

More News
Evotec and Indivumed Announce Second Joint Drug Discovery Program

HAMBURG, Germany , Jan. 23, 2020 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH ("Indivumed") today announced that the companies have...

EVTCY : 48.2000 (-2.33%)
Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

CELGZ : 0.47 (+2.15%)
NVS : 86.02 (-1.25%)
NVO : 59.49 (-2.64%)
GNHAF : 175.0693 (-9.36%)
EVTCY : 48.2000 (-2.33%)
Evotec Achieves Third Milestone In Cell Therapy Diabetes Alliance With Sanofi

SIGNIFICANT PROGRESS MADE TOWARDS A BETA CELL REPLACEMENT THERAPY FOR PEOPLE WITH DIABETESEVOTEC RECEIVES EUR 3 M PAYMENT FROM SANOFI

CELGZ : 0.47 (+2.15%)
NVS : 86.02 (-1.25%)
NVO : 59.49 (-2.64%)
EVTCY : 48.2000 (-2.33%)
Evotec Expands Service Agreement With Sanofi To Create A Centralised Global Sample Management Hub In Toulouse

CENTRALISATION OF SAMPLE COMPOUNDS IN TOULOUSE PROVIDES GREATER EFFICIENCY FOR SANOFI'S SMALL MOLECULE DRUG DISCOVERY EFFORTSLATEST DISPENSING TECHNOLOGY WILL HELP OPTIMISE COMPOUND ACCESS ACROSS GLOBAL...

CELGZ : 0.47 (+2.15%)
NVS : 86.02 (-1.25%)
NVO : 59.49 (-2.64%)
EVTCY : 48.2000 (-2.33%)
Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

CELGZ : 0.47 (+2.15%)
NVS : 86.02 (-1.25%)
NVO : 59.49 (-2.64%)
GNHAF : 175.0693 (-9.36%)
EVTCY : 48.2000 (-2.33%)
Evotec Reaches Milestone In Integrated Drug Discovery And Development Partnership With Aeovian

PARTNERSHIP ACHIEVES FAST-TRACK PROGRESS FROM LEAD OPTIMISATION TO NOMINATION OF A PRE-CLINICAL DEVELOPMENT CANDIDATE ("PDC") IN 18 MONTHSEVOTEC RECEIVES UNDISCLOSED PAYMENT AND HAS SECURED AN EQUITY STAKE...

EVTCY : 48.2000 (-2.33%)
Evotec And Indivumed Achieve Milestone In Joint Strategic Drug Discovery Collaboration

HAMBURG, Germany , Sept. 30, 2019 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that the first milestone has been successfully...

EVTCY : 48.2000 (-2.33%)
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

LJPC : 6.73 (-2.89%)
EVTCY : 48.2000 (-2.33%)
SLNO : 2.66 (-8.28%)
ASRT : 1.05 (-5.41%)
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment

Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.

NEOS : 1.54 (-1.91%)
EVTCY : 48.2000 (-2.33%)
CPIX : 4.10 (-1.44%)
ACER : 3.59 (-8.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade EVTCY with:

Key Turning Points

2nd Resistance Point 50.2440
1st Resistance Point 49.7960
Last Price 48.2000
1st Support Level 49.1240
2nd Support Level 48.9000

See More

52-Week High 59.5000
Fibonacci 61.8% 52.3069
Fibonacci 50% 50.0850
Last Price 48.2000
Fibonacci 38.2% 47.8631
52-Week Low 40.6700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar